Name: Latest research reports of Sun Pharmaceutical Industries Ltd. authored by Emkay and published by - Trendlyne research reports.
Item: Sun Pharmaceutical Industries Ltd.
Rating: 5
Author: Emkay

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report	Discuss
	09 Sep 2025	Sun Pharmaceutical	Consensus Share Price Target	1580.90	1930.16	-	22.09	buy	pdf Detailed Estimates
	10 Apr 2025	Sun Pharmaceutical	Emkay	1580.90	2400.00	1652.20 (-4.32%)	51.81	Buy	pdf post cache	Broker Report Order vacating injunction on Leqselvi a material positive Emkay The US Court of Appeals has vacated the preliminary injunction against Sun Pharma’s launch of Leqselvi which was granted by the US District Court of New Jersey in Nov-24. pdf Copy Link Share on Share on Share on Share on Alert
	11 Mar 2025	Sun Pharmaceutical	ICICI Securities Limited Reco Target	1580.90	1895.00	1655.30 (-4.49%)	19.87	Buy	pdf post cache	Broker Report On a spree to expand specialty portfolio ICICI Securities Limited Sun Pharma (Sun) is acquiring US-based early-stage oncology-focused biotech company Checkpoint Therapeutics (Checkpoint) for an upfront cash payment of USD 4.1/share (total outgo of USD 355mn) and USD 0.7/share in cash in future milestones. pdf Copy Link Share on Share on Share on Share on Alert
	10 Mar 2025	Sun Pharmaceutical	BOB Capital Markets Ltd.	1580.90	2086.00	1611.50 (-1.90%)	31.95	Buy	pdf post cache	Broker Report Sun Pharma (BUY): Acquiring Checkpoint Therapeutic to widen Specialty portfolio BOB Capital Markets Ltd. SUNP to acquire Checkpoint Therapeutic for US$ 4.10 a share, at ~66% premium to its last closing price. Deal valued at US$ 355mn pdf Copy Link Share on Share on Share on Share on Alert
	01 Feb 2025	Sun Pharmaceutical	BOB Capital Markets Ltd. Reco Target	1580.90	2086.00	1742.20 (-9.26%)	31.95	Buy	pdf post cache	Broker Report Sun Pharma (BUY): Strong performance to continue BOB Capital Markets Ltd. Domestic sales grew by 14% in Q3FY25 driven partially by volume/new launches and price hikes. Strong domestic sales growth to continue pdf Copy Link Share on Share on Share on Share on Alert
	21 Jan 2025	Sun Pharmaceutical	Emkay Target	1580.90	2400.00	1762.70 (-10.31%)	51.81	Buy	pdf post cache	Broker Report Addressing the oral IL-23 antagonist challenge to Ilumya Emkay J&J, in a recent investor interaction, had stated that its oral IL-23 receptor antagonist peptide (Icotrokinra) could potentially compete with existing oral as well as injectable treatment options for moderate to severe plaque psoriasis. pdf Copy Link Share on Share on Share on Share on Alert
	29 Oct 2024	Sun Pharmaceutical	ICICI Direct Reco Target	1580.90	2185.00	1871.60 (-15.53%)	38.21	Buy	pdf post cache	Broker Report Sun Pharma ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	29 Oct 2024	Sun Pharmaceutical	BOB Capital Markets Ltd. Target	1580.90	2019.00	1871.60 (-15.53%)	27.71	Hold	pdf post cache	Broker Report Sun Pharma (HOLD): All positives built into current valuations BOB Capital Markets Ltd. SUNP reported 11% domestic sales growth led by 5% volume growth from ~14,000 MRs; leads in Rx count across 13 doctor categories pdf Copy Link Share on Share on Share on Share on Alert
	28 Oct 2024	Sun Pharmaceutical	Sharekhan Target	1580.90	2264.00	1902.90 (-16.92%)	43.21	Buy	pdf post cache	Broker Report Company surpasses expectations across multiple metrics Sharekhan Sun Pharmaceutical Industries reported a revenue of ?13,291 crore for the quarter, reflecting a 9% year-over-year increase and a 5% rise quarter-over-quarter. This figure surpassed our estimates by 2%, despite experiencing price reductions in Taro’s portfolio and in Japan. pdf Copy Link Share on Share on Share on Share on Alert
	02 Aug 2024	Sun Pharmaceutical	ICICI Direct Target	1580.90	1845.00	1731.65 (-8.71%)	Target met	Hold	pdf post cache	Broker Report Sun Pharma ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	01 Aug 2024	Sun Pharmaceutical	Motilal Oswal Target	1580.90	1980.00	1715.20 (-7.83%)		Buy	pdf post cache	Broker Report Specialty/DF drive earnings Motilal Oswal Sun Pharma (SUNP) delivered better-than-expected 1QFY25 earnings, led by an improved segmental mix and lower RM costs. pdf Copy Link Share on Share on Share on Share on Alert
	20 Jun 2024	Sun Pharmaceutical	Sharekhan Target	1580.90	1800.00	1471.00 (7.47%)	Target met	Buy	pdf post cache	Broker Report Dadra facility receiving WL to have no impact on the company’s financials Sharekhan Sun Pharma’s Dadra facility received a Warning Letter for a violation of cGMP regulations, which had previously received an Official Action Indicated (OAI) status on 11th Apr’24. pdf Copy Link Share on Share on Share on Share on Alert
	10 Jun 2024	Sun Pharmaceutical	Geojit BNP Paribas Reco Target	1580.90	1655.00	1513.10 (4.48%)	Target met	Hold	pdf post cache	Broker Report SUN PHARMA Geojit BNP Paribas pdf Copy Link Share on Share on Share on Share on Alert
	23 May 2024	Sun Pharmaceutical	ICICI Securities Limited Target	1580.90	1463.00	1495.10 (5.74%)	Target met	Hold	pdf post cache	Broker Report Steady quarter, valuation quite pricey ICICI Securities Limited Sun Pharma (Sun)’s Q4FY24 results were aided by higher other income, barring which, performance was marginally below our expectations. pdf Copy Link Share on Share on Share on Share on Alert
	23 May 2024	Sun Pharmaceutical	BOB Capital Markets Ltd. Target	1580.90	1530.00	1495.10 (5.74%)	Target met	Hold	pdf post cache	Broker Report Sun Pharma (HOLD): Gearing for higher R&D spend BOB Capital Markets Ltd. SUNP missed consensus EBITDA estimate by 4% as higher R&D spend offset gross margin gains; higher other income & low tax aided PAT pdf Copy Link Share on Share on Share on Share on Alert
	23 May 2024	Sun Pharmaceutical	ICICI Direct Reco Target	1580.90	1530.00	1495.10 (5.74%)	Target met	Hold	pdf post cache	Broker Report Sun Pharma ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	22 May 2024	Sun Pharmaceutical	Motilal Oswal Target	1580.90	1810.00	1539.30 (2.70%)	Target met	Buy	pdf post cache	Broker Report The US and India businesses drive earnings growth Motilal Oswal Sun Pharma (SUNP) reported a slight miss at the operational level for 4QFY24. This was due to lower-than-expected sales in the ROW market and higher-than-expected opex for the quarter. pdf Copy Link Share on Share on Share on Share on Alert
	23 Apr 2024	Sun Pharmaceutical	Motilal Oswal Target	1580.90	1870.00	1484.65 (6.48%)	Target met	Buy	pdf post cache	Broker Report ‘Specialty’ way of driving growth prospects Motilal Oswal In this note, we explored the specialty pipeline of SUNP, examining products under development, the commercialized portfolio, and the competitive dynamics within each segment. pdf Copy Link Share on Share on Share on Share on Alert
	11 Mar 2024	Sun Pharmaceutical	Sharekhan Target	1580.90	1727.00	1584.30 (-0.21%)	Target met	Buy	pdf post cache	Broker Report Sun Pharma Sharekhan pdf Copy Link Share on Share on Share on Share on Alert
	01 Feb 2024	Sun Pharmaceutical	BOB Capital Markets Ltd. Target	1580.90	1550.00	1407.95 (12.28%)	Target met	Hold	pdf post cache	Broker Report Sun Pharma (HOLD): Strong quarter driven by specialty business BOB Capital Markets Ltd. Strong quarter with revenue/EBITDA in line and reported PAT 4% ahead of Bloomberg consensus pdf Copy Link Share on Share on Share on Share on Alert
	01 Feb 2024	Sun Pharmaceutical	SMC online	1580.90		1407.95 (12.28%)		Results Update	pdf post cache	Broker Report Sun Pharmaceuticals Industries SMC online pdf Copy Link Share on Share on Share on Share on Alert
more loading

Near 52W Low of ₹1553.05

Sun Pharmaceutical Industries Ltd. share price target

Sun Pharmaceutical Industries Ltd. has an average share price target of 2050.25. The consensus estimate represents an upside of 29.69% from the last price of 1580.90. View 14 reports from 8 analysts offering long-term price targets for Sun Pharmaceutical Industries Ltd..

Order vacating injunction on Leqselvi a material positive

On a spree to expand specialty portfolio

Sun Pharma (BUY): Acquiring Checkpoint Therapeutic to widen Specialty portfolio

Sun Pharma (BUY): Strong performance to continue

Addressing the oral IL-23 antagonist challenge to Ilumya

Sun Pharma

Sun Pharma (HOLD): All positives built into current valuations

Company surpasses expectations across multiple metrics

Sun Pharma

Specialty/DF drive earnings

Dadra facility receiving WL to have no impact on the company’s financials

SUN PHARMA

Steady quarter, valuation quite pricey

Sun Pharma (HOLD): Gearing for higher R&D spend

Sun Pharma

The US and India businesses drive earnings growth

‘Specialty’ way of driving growth prospects

Sun Pharma

Sun Pharma (HOLD): Strong quarter driven by specialty business

Sun Pharmaceuticals Industries

Advisor Screeners